Publication Name	World Journal of Gastroenterology
Manuscript ID	6933
Country	South Korea

Received	2013-10-30 18:36
Peer-Review Started	2013-11-01 11:35
To Make the First Decision	2013-12-16 18:13
Return for Revision	2013-12-18 11:33
Revised	2014-01-14 17:03
Second Decision	2014-04-16 11:15
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-04-16 12:15
Articles in Press	2014-05-23 10:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-16 12:41
Publish the Manuscript Online	2014-08-07 10:34

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Woo-Jeong Jeong, Pu-Hyeon Cha and Kang-Yell Choi
Funding Agency and Grant Number
Corresponding Author	Kang-Yell Choi, Professor, Translational Research Center for Protein Function Control, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, 134 Shinchon-Dong, Seodemun-Gu, Seoul 120-749, South Korea. kychoi@yonsei.ac.kr
Key Words	Colorectal cancer; Epidermal growth factor receptor; Resistance; K-ras mutation; Combinational therapy
Core Tip	Personalized treatment of patients with metastatic colorectal cancer (mCRC) based on genetic profiling of individual tumors is considered the future direction of cancer therapy. The important discovery that mutation of the K-ras gene is a predictor of resistance to epidermal growth factor receptor (EGFR) monoclonal antibodies is only the first of a series of genetic predictors and an increasing number of molecular alterations have since been hypothesized to play a role in resistance to anti-EGFR drugs in CRC, including activating mutations in B-Raf and PIK3CA, and loss of expression of PTEN. A comprehensive molecular characterization of mCRC and a better understanding of the functional interactions within the RTK-activated intracellular pathway will be necessary in order to select the most appropriate therapy for each individual patient.
Publish Date	2014-08-07 10:34
Citation	Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871
URL	http://www.wjgnet.com/1007-9327/full/v20/i29/9862.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i29.9862

Full Article (PDF)	WJG-20-9862.pdf
Full Article (Word)	WJG-20-9862.doc
Manuscript File	6933-Review.docx
Answering Reviewers	6933-Answering reviewers.pdf
Copyright License Agreement	6933-Copyright assignment.pdf
Peer-review Report	6933-Peer reviewer(s).pdf
Scientific Editor Work List	6933-Scientific editor work list.doc